Please try another search
For the nine months ended 30 September 2017, Biostar Pharmaceuticals Inc revenues decreased from $2.1M to $0K. Net loss decreased 73% to $2.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Provision for doubtful debt decrease from $7.8M (expense) to $0K, Selling expenses decrease of 67% to $300K (expense).
Period Ending: | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0.32 |
Gross Profit | 0 | 0 | 0 | -0.04 |
Operating Income | -0.57 | -1.53 | -1.04 | 5.93 |
Net Income | -0.13 | -1.31 | -1.01 | 3.39 |
Period Ending: | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Total Assets | 41.43 | 40.78 | 41.49 | 42.5 |
Total Liabilities | 5.28 | 5.29 | 5.31 | 5.62 |
Total Equity | 36.15 | 35.49 | 36.18 | 36.88 |
Period Ending: | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | 4.59 | 4.59 | 0.32 | 4.91 |
Cash From Investing Activities | -4.41 | -4.36 | 0 | -6.38 |
Cash From Financing Activities | 0 | 0 | 0 | 1.41 |
Net Change in Cash | 0.19 | 0.23 | 0.31 | 0.13 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review